Trevi Therapeutics, Inc. (TRVI) Aims To Calm Severe Itch

Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biotech built around Haduvio, an oral drug for stubborn chronic cough in idiopathic pulmonary fibrosis and the intense itch of prurigo nodularis. It targets the nerve pathways that keep cough and itch stuck in overdrive, so people can finally sleep, function, and feel normal again. Growth potential leans on late-stage trial data, regulator decisions, and doctors hungry for better options in these hard-to-treat conditions.

On the chart, TRVI just printed a confirmation bar with rising volume as price moved above the 0.236 Fibonacci level and into the momentum zone. From here, traders can use the Fibonacci snap tool to keep a trailing stop tucked just under that 0.236 line, giving the trend room to work while keeping a clear, rule-based exit if momentum fades.